Fate Therapeutics receives FDA clearance for FT839 IND

• Fate Therapeutics received FDA clearance for its investigational new drug application regarding its FT839 product candidate.
• The dual-CAR T-cell candidate targets both CD19 and CD38 for autoimmune diseases and hematologic cancers.
• Management stated a Phase 1/2 basket trial will begin enrolling subjects during the second half of 2026.

Fate Therapeutics (NASDAQ:FATE) received FDA clearance for its investigational new drug application regarding the FT839 candidate.

The regulatory approval advances an off-the-shelf, dual-CAR T-cell therapy targeting autoimmune diseases and hematologic cancers.

The FT839 treatment functions by co-targeting both the CD19 and CD38 cellular markers within patients.

The business expects to begin enrolling patients for a Phase 1/2 basket trial during the second half of 2026.

The firm anticipates further clinical advancements.

The FT839 development expands the ongoing corporate focus on engineering advanced cellular immunotherapies for complex diseases.

Management stated this new trial design provides an additional therapeutic pathway alongside its broader oncology portfolio.